EUVIMEDEUVIMED entdecken
Crossref

Targeting RIPK1 is a promising therapeutic avenue for systemic lupus erythematosus

Ming Chen, Liyan Wan, Minhui Wang, Junyu Liang, Yini Ke, Mengdi Jiang, Jing Liu, Heng Cao

Clinical Rheumatology · 2026-07 · 45 (7) · 4241-4253

DOI: 10.1007/s10067-026-08080-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, online erschienen am 19.06.2026. Verfasst von Ming Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Road Qingchun, Hangzhou, Zhejiang Province,…. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Indoles, Lupus Erythematosus, Systemic, Imidazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor-Interacting Protein Serine-Threonine KinasesIndolesLupus Erythematosus, SystemicImidazolesNecroptosisLupus NephritisAnimalsHumansMice, Inbred MRL lprFemaleMiceAdultKidneyDisease Models, AnimalTh17 Cells

Stichwörter der Autor:innen

Lupus nephritisNecroptosisNecrostatin-1Systemic lupus erythematosus

Substanzen

necrostatin-1Receptor-Interacting Protein Serine-Threonine KinasesIndolesImidazolesRipk1 protein, mouseRIPK1 protein, human

Autor:innen und Institutionen

  • Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Road Qingchun, Hangzhou, Zhejiang Province, 310003, China.
  • National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Nanjing Medical University, 305 East Zhongshan Road, Nanjing , Jiangsu, 210018, China. ruby017@163.com.
  • Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Road Qingchun, Hangzhou, Zhejiang Province, 310003, China. caohengzju@126.com.

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • Foundation of Jinling Hospital

Zitieren

APA

Chen, M., Wan, L., Wang, M., Liang, J., Ke, Y., Jiang, M., Liu, J., & Cao, H. (2026). Targeting RIPK1 is a promising therapeutic avenue for systemic lupus erythematosus. Clinical Rheumatology, 45(7), 4241-4253. https://doi.org/10.1007/s10067-026-08080-4

Vancouver

Chen M, Wan L, Wang M, Liang J, Ke Y, Jiang M, et al. Targeting RIPK1 is a promising therapeutic avenue for systemic lupus erythematosus. Clinical Rheumatology. 2026;45(7):4241-4253. doi:10.1007/s10067-026-08080-4

BibTeX
@article{Chen2026,
  author = {Chen, Ming and Wan, Liyan and Wang, Minhui and Liang, Junyu and Ke, Yini and Jiang, Mengdi and Liu, Jing and Cao, Heng},
  title = {Targeting RIPK1 is a promising therapeutic avenue for systemic lupus erythematosus},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {7},
  pages = {4241--4253},
  doi = {10.1007/s10067-026-08080-4}
}
Kostenlos starten →